Validation of RSSDI therapeutic wheel with clinical experience of Indian physicians

Hasnani, Dhruvi; Chavda, Vipul; Agrawal, Dinesh Kumar; Patni, Bijay; David, Ashwin; Gathe, Sachin; Chawla, Rajeev; Kesavadev, Jothydev; Gupta, Sunil; Hasnani, Shriji; Saboo, Banshi

doi:10.1007/s13410-021-00998-6

Int J Diabetes Dev Ctries

2021

DOI: 10.1007/s13410-021-00998-6

|View full text |Cite

Validation of RSSDI therapeutic wheel with clinical experience of Indian physicians

Dhruvi Hasnani

Vipul Chavda

Dinesh Kumar Agrawal³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, DPP-4 inhibitors ranked as the second most commonly prescribed OAD after metformin for patients with chronic kidney disease (CKD) or CVD. 6 Vildagliptin, a DPP-4 inhibitor, effectively reduces HbA1c levels in patients with T2DM when used as monotherapy, dual, or triple combination therapy. In India, vildagliptin is commonly prescribed for T2DM patients due to its ability to decrease the mean amplitude of glycemic excursion, its lower risk of hypoglycemia, and its weightneutral profile.…”

mentioning

confidence: 99%

Expert opinion on the prescription practice of vildagliptin and its combinations in managing type 2 diabetes mellitus in Indian settings

S.,

2024

Int J Adv Med

View full text Add to dashboard Cite

Background: The aim of the study was to gather expert opinion regarding the use of vildagliptin and its combinations in T2DM in Indian settings. Methods: This cross-sectional study involved 24 questions and collected perspectives of experts across various clinical settings in India regarding the use of vildagliptin and its combinations for the management of type 2 diabetes mellitus (T2DM) in their clinical practice. Results: Among 195 participants, most clinicians (73%) advocated vildagliptin once-daily formulation for newly diagnosed young diabetics, elderly patients with long-standing diabetes, and those with uncontrolled diabetes as an add-on therapy. Around 92% favored vildagliptin for its weight-neutral nature, preservation of beta-cell function, minimal glycemic variation, and low risk of adverse effects. Most clinicians (66%) preferred initiating vildagliptin and metformin combination therapy in diabetic individuals aged 40 to 50 years, with 53% opting for it when HbA1c levels exceeded 8%. Approximately 83% favored this combination for young, elderly, and long-standing diabetic individuals. More than half (54%) of the clinicians preferred prescribing the fixed-dose combination (FDC) of vildagliptin and dapagliflozin to 11-25% of the patients. Conclusions: The survey underscored the effectiveness of vildagliptin and its combinations in managing T2DM. Clinicians widely endorsed vildagliptin once-daily formulation and vildagliptin and metformin therapy for diverse diabetic populations due to their efficacy and tolerability. They also advocated the use of vildagliptin and dapagliflozin therapy, especially in patients with specific comorbidities or higher HbA1c levels, citing its benefits in achieving better glycemic control and reducing disease progression.

show abstract

mentioning

confidence: 99%

Expert opinion on the prescription practice of vildagliptin and its combinations in managing type 2 diabetes mellitus in Indian settings

S.,

2024

Int J Adv Med

View full text Add to dashboard Cite

show abstract

Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective

Kalra,

Zargar,

Sridhar

et al. 2024

Clin Med Insights Endocrinol Diabetes

View full text Add to dashboard Cite

Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Validation of RSSDI therapeutic wheel with clinical experience of Indian physicians

Cited by 2 publications

References 23 publications

Expert opinion on the prescription practice of vildagliptin and its combinations in managing type 2 diabetes mellitus in Indian settings

Expert opinion on the prescription practice of vildagliptin and its combinations in managing type 2 diabetes mellitus in Indian settings

Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective

Contact Info

Product

Resources

About